Foundations supporting neuroprosthetic management of hypotensive complications in PD

Ecole Polytechnique Federale De Lausanne (EPFL) received a $199,966 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective August 1, 2025, through July 31, 2027. The award supports research titled "Foundations Supporting Neuroprosthetic Management of Hypotensive Complications in Parkinson's Disease," addressing a critical neurological health challenge affecting military service members and the general population. EPFL will deliver advanced biomedical research and development services focused on developing neuroprosthetic technologies and therapeutic interventions to manage orthostatic hypotension and related cardiovascular complications associated with Parkinson's disease.

This project grant represents the DHA's investment in hypothesis-driven, translational research that combines EPFL's established expertise in biomedical engineering and neuroprosthetic device development with the federal priority to transform healthcare through innovative medical solutions. The two-year performance period aligns with typical Military Medical Research and Development program awards, which generally range from two to four years and emphasize research with direct relevance to military health priorities and broader public health applications.